Carcinoid syndrome historical perspective

Revision as of 14:25, 26 December 2018 by Anum Gull (talk | contribs) (→‎Overview)
Jump to navigation Jump to search

Carcinoid syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Carcinoid Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Carcinoid syndrome historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Carcinoid syndrome historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Carcinoid syndrome historical perspective

CDC on Carcinoid syndrome historical perspective

Carcinoid syndrome historical perspective in the news

Blogs on Carcinoid syndrome historical perspective

Directions to Hospitals Treating Carcinoid syndrome

Risk calculators and risk factors for Carcinoid syndrome historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

The term Carcinoid was given by Siegfried Oberndorfer, a German pathologist at the University of Munich in 1907.Enterochromaffin cell,the cell of origin of carcinoid tumour had been identified as early as 1897 by N. Kulchitsky (1856-1925)

Historical Perspective

  • Theodor Langhans (1839–1915) was the first to describe the histology of a carcinoid tumor in 1867.
  • The term Carcinoid was given by Siegfried Oberndorfer, a German pathologist at the University of Munich in 1907.
  • Siegfried Oberndorfer refered the carcinoid tumor as "benign carcinomas" as they had distinct clinical entities and named them "karzinoide"(carcinoma-like).
  • Karzinoide or “carcinoma-like” describes the unique feature of behaving like a benign tumor despite resembling a carcinoma microscopically.
  • Rapport and colleagues isolated and named serotonin (5-HT), initially identified as a vasoconstrictor substance in the serum.[1]
  • Enterochromaffin cell,the cell of origin of carcinoid tumour had been identified as early as 1897 by N. Kulchitsky (1856-1925).
  • F. Lembeck in 1953 established that enterochromaffin cells synthesizes and secretes serotonin and a major hormone responsible for carcinoid syndrome.[2][3]

References

  1. RAPPORT MM, GREEN AA, PAGE IH (December 1948). "Serum vasoconstrictor, serotonin; isolation and characterization". J. Biol. Chem. 176 (3): 1243–51. PMID 18100415.
  2. ERSPAMER V, ASERO B (May 1952). "Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine". Nature. 169 (4306): 800–1. PMID 14941051.
  3. Sippel RS, Chen H (July 2006). "Carcinoid tumors". Surg. Oncol. Clin. N. Am. 15 (3): 463–78. doi:10.1016/j.soc.2006.05.002. PMID 16882492.

Template:WH Template:WS

References

Template:WS Template:WH